Elena Peeva Selected Research

Tec protein-tyrosine kinase

1/2022	Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
10/2020	Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elena Peeva Research Topics

Disease

9	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2015 - 05/2005
5	Autoimmune Diseases (Autoimmune Disease) 06/2015 - 06/2007
4	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 01/2018
4	Hyperprolactinemia 06/2009 - 06/2004
3	Alopecia (Baldness) 01/2022 - 01/2020
3	Rheumatoid Arthritis 10/2020 - 06/2015
2	Alopecia Areata 01/2022 - 01/2021
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2020
2	Atopic Dermatitis (Atopic Eczema) 10/2021 - 12/2019
2	Eczema 10/2021 - 12/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2021
1	Pruritus (Itching) 10/2021
1	Herpes Simplex 10/2020
1	Infections 10/2020
1	Skin Diseases (Skin Disease) 10/2020
1	Alopecia universalis 01/2020
1	Inflammation (Inflammations) 01/2020
1	Multiple Sclerosis 06/2015
1	Glomerulonephritis 11/2013
1	Lupus Nephritis 11/2013
1	Proteinuria 11/2013
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 08/2012
1	Infertility (Sterility) 12/2010
1	Neoplasms (Cancer) 07/2006
1	Prolactinoma (Prolactinomas) 07/2006
1	Genetic Predisposition to Disease (Genetic Predisposition) 05/2005
1	Abdominal Aortic Aneurysm 02/2005
1	Aneurysm (Aneurysms) 02/2005

Drug/Important Bio-Agent (IBA)

5	ProlactinIBA 02/2011 - 06/2004
5	Gonadal Steroid Hormones (Sex Hormones)IBA 02/2011 - 05/2005
3	SaltsIBA 01/2022 - 01/2020
3	PF-06700841IBA 12/2020 - 01/2018
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 10/2020
2	Tec protein-tyrosine kinaseIBA 01/2022 - 10/2020
2	Janus Kinase InhibitorsIBA 01/2022 - 01/2021
2	TYK2 Kinase (Tyrosine Kinase 2)IBA 01/2022 - 01/2022
2	abrocitinibIBA 10/2021 - 12/2019
2	Janus Kinase 1IBA 01/2020 - 12/2019
2	AutoantibodiesIBA 11/2013 - 05/2005
2	Estrogens (Estrogen)FDA Link 08/2010 - 05/2005
2	DNA (Deoxyribonucleic Acid)IBA 08/2006 - 03/2006
1	Janus KinasesIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	ropsacitinibIBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021
1	LigandsIBA 11/2021
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 10/2021
1	PF-06651600IBA 10/2020
1	Antiviral Agents (Antivirals)IBA 10/2020
1	Methotrexate (Mexate)FDA LinkGeneric 10/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020
1	CytokinesIBA 01/2020
1	SBI-087IBA 12/2016
1	Progestins (Progestagens)IBA 06/2015
1	5- amino- 1- (1- cyanopiperidin- 3- yl)- 3- (4- (2,4- difluorophenoxy)phenyl)- 1H- pyrazole- 4- carboxamideIBA 11/2013
1	Antigen-Antibody Complex (Immune Complex)IBA 11/2013
1	Selective Estrogen Receptor Modulators (SERM)IBA 08/2010
1	CalciumIBA 06/2009
1	Hormones (Hormone)IBA 07/2006
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 05/2005

Therapy/Procedure

6	Therapeutics 01/2022 - 12/2008
1	Contraindications 12/2019
1	Induced Labor 12/2010
1	Ligation 02/2005